Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 6/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND3 | P30281 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341355 | 0.91 | VCP (0.40) | VCPALDH1A1PTGS2IDO1CYP2C9 | |
| SCHEMBL3420464 | 0.86 | PTGS2 (0.39) | VCPSMN1; SMN2MAPTALDH1A1PTGS2 | |
| SCHEMBL3423997 | 0.85 | PTGS2 (0.39) | VCPSMN1; SMN2MAPTALDH1A1PTGS2 | |
| SCHEMBL3230131 | 0.84 | VCP (0.47) | VCP | |
| SCHEMBL3225982 | 0.82 | VCP (0.47) | VCPALDH1A1 | |
| SCHEMBL3223357 | 0.80 | SMN1; SMN2 (0.38) | VCPSMN1; SMN2MAPTALDH1A1PTGS2 | |
| SCHEMBL3228961 | 0.78 | MAPT (0.47) | VCPSMN1; SMN2MAPTPTGS2LMNA | |
| SCHEMBL3261463 | 0.76 | MAPT (0.44) | MAPTLMNA | |
| SCHEMBL13456811 | 0.76 | VCP (0.44) | VCPHRH3 | |
| SCHEMBL3232625 | 0.76 | AKT1 (0.40) | MAPTALDH1A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | claimed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | GATAD2B, GATAD2A, RUNX1 | VCP 4664/4885SMN1; SMN2 2766/4885MAPT 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.